Christopher M. Gleeson

Filings by Christopher M. Gleeson span 2 companies, the busiest being Ventana Medical Systems Inc and GenMark Diagnostics, Inc. Between 3 March 2006 and 29 May 2014, the trades on record add up to 78 filings.

In open-market terms, that means 3 purchases worth €6.9M on one side and 5 sales worth €3.3M on the other. Netting one side against the other leaves €3.6M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 12 share grants and 50 option exercises.

A typical purchase (the median) is worth €202k.

On 2 June 2014 came the latest disclosure, a share grant in GenMark Diagnostics, Inc. The latest purchase dates back some time: it was published 5,246 days ago, on 28 June 2012. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.